NCT02265627已完成1 期
Pharmacokinetics, Safety and Tolerability of Single Dose BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Subjects (An Open Label, Matched Pair, Two Center Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 主要终点
- Plasma concentration-time profiles of the analytes at different time points
研究概览
简要总结
To investigate the pharmacokinetics of a single dose of BIIL 284 BS in patients with hepatic impairment in comparison to healthy subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 24 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy Subjects
- •Written informed consent signed and dated prior to participation into the study (including medication washout)
- •Male of female 24-70 years of age
- •All subjects should be within (+- 20 %) of their ideal body weight (Broca-Index)
- •Healthy subjects must be able to be comparably matched to a hepatic impaired patient according to age (+- 5 years), weight (+- 30 lbs), gender, and smoking status
- •Volunteers will have no evidence of clinically relevant concomitant disease based upon the following: a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, complete blood count (CBC) with differential and platelets, prothrombin time (PT), blood chemistry, hematology and urinalysis
- •Female subjects need to be of non-childbearing potential (post-menopausal), tubal ligation or total hysterectomy) and had to provide a negative pregnancy test at the screening visit or subjects is a male
- •Tested negative at the screening visit for the following drug screen panel (barbiturates, benzodiazepines, amphetamines, opiates, cocaine, cannabinoids)
- •Patients with hepatic impairment
- •Written informed consent signed and dated prior to participation into the study (including medication washout)
- •Male of female 24-70 years of age
- •All subjects should be within (+- 20 %) of their ideal body weight (Broca-Index)
- •Proven history of cirrhosis confirmed by liver/spleen scan or biopsy (within one year)
- •Hepatic impairment: A Child-Pugh classification of Class A, or B
- •Volunteers will have no evidence of clinically relevant concomitant disease (other than hepatic impairment) based upon the following: a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, CBC with differential and platelets, prothrombin time (PT), blood chemistry, hematology and urinalysis
- •Tested negative at the screening visit for the following drug screen panel (barbiturates, benzodiazepines, amphetamines, opiates, cocaine, cannabinoids). Unless known drugs were being used for medicinal reasons. For this reason the sponsor and investigator were notified
- •Female patients were of non-childbearing potential (post-menopausal), tubal ligation or total hysterectomy) and had to provide a negative pregnancy test at the screening visit
排除标准
- •Healthy subjects
- •Tested positive for Hepatitis B surface antigen, Hepatitis C antibody or HIV antibody
- •Have a significant acute or chronic disease, which could have interfered with the objectives of the study
- •Small or difficult to locate arm or hand veins that would impair the clinician's ability to draw multiple blood samples or to place a venous catheter
- •Likely to need concomitant medication during the study period, which could interfere with the objectives of the study
- •Had given a blood donation during the month preceding the study drug administration
- •Alcohol consumption > 2 drinks daily (one drink defined as: 12 ounces of beer, 4 ounces of wine or 1.5 ounces of spirits)
- •Coffee or tea consumption > 3 cups per day or xanthine containing drinks > 0.5 liter/day
- •History of any clinically significant hematological, respiratory, cardiovascular, renal or central nervous system (CNS) disease or other medical condition that is capable of altering the metabolism or elimination of drugs, or of constituting a risk factor when taking the study drug
- •History of drug addiction or alcoholism
- •Any medical or psychological condition which could relapse during or immediately after the study
- •Use of any drug or nutrient which could induce or inhibit hepatic microsomal enzymes within one month of the start of the study or longer based on the elimination half-life of the drug
- •Use of experimental new drug one month prior to study drug administration
- •Consumed any medicine whatsoever (including over the counter (OTC) drugs) within two weeks of the scheduled administration of the study drug
- •Patients with Hepatic Impairment
- •Positive serology for HIV
- •Have a significant acute or chronic disease (except hepatic disease), which is unstable or could interfere with the objectives of the study
- •Small or difficult to locate arm or hand veins that would impair the clinician's ability to draw multiple blood samples or to place a venous catheter
- •Have hepatocellular carcinoma, extrahepatic biliary obstruction, surgical portal-systemic shunting, acute hepatitis of any origin
- •Digestive bleeding within one month of inclusion
- •Likely to need concomitant medication during the study period, which could interfere with the objectives of the study
- •Had given a blood donation during the month preceding study entry
- •Coffee or tea consumption > 3 cups per day or xanthine containing drinks > 0.5 liter/day
- •History of any clinically significant hematological, respiratory, cardiovascular, renal or CNS disease or other medical condition (except hepatic impairment) that is capable of altering the metabolism or elimination of drugs, or of constituting a risk factor when taking the study drug
- •Any medical or psychological condition which could relapse during or immediately after the study
- •Use of any drug or nutrient which could induce or inhibit hepatic microsomal enzymes within one month of the start of the study or longer based on the elimination half-life of the drug
- •Use of experimental new drug within the previous month
研究组 & 干预措施
BIIL 284 BS, mild hepatic impairment
Experimental
干预措施: BIIL 284 BS (Drug)
BIIL 284 BS, normal hepatic function
Experimental
干预措施: BIIL 284 BS (Drug)
BIIL 284 BS, moderate hepatic impairment
Experimental
干预措施: BIIL 284 BS (Drug)
结局指标
主要结局
Plasma concentration-time profiles of the analytes at different time points
时间窗: Up to 84 hours after drug administration
次要结局
- Maximum measured concentration of BIIL 315 ZW in plasma (Cmax)(Up to 84 hours after drug administration)
- Time from dosing to the maximum concentration of BIIL 315 ZW in plasma (tmax)(Up to 84 hours after drug administration)
- Area under the concentration-time curve of BIIL 315 ZW in plasma at different time points (AUC)(Up to 84 hours after drug administration)
- Terminal half-life of BIIL 315 ZW in plasma (t1/2)(Up to 84 hours after drug administration)
- Total mean residence time of BIIL 315 ZW in the body (MRTtot)(Up to 84 hours after drug administration)
- Total apparent clearance of BIIL 315 ZW in plasma after oral administration (CLtot/F)(Up to 84 hours after drug administration)
- Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)(Up to 84 hours after drug administration)
- Number of patients with clinically relevant findings in vital signs(Up to 4 days after drug administration)
- Changes from baseline in spirometry(Pre-dose and 1 hour after drug administration)
- Number of patients with clinically relevant findings in laboratory tests(Up to 4 days after drug administration)
- Number of patients with clinically relevant findings in 12-lead ECG(Up to 4 days after drug administration)
- Changes from baseline in physical examination(Pre-dose and 4 days after drug administration)
- Number of patients with adverse events(Up to 11 days after drug administration)
研究者
相似试验
已完成
1 期
Effect of BIIL 284 BS on the Pharmacokinetics of Theophylline in Healthy Male VolunteersHealthyNCT02273440Boehringer Ingelheim16
已完成
1 期
Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy SubjectsInfection, Human Immunodeficiency VirusNCT02467335ViiV Healthcare52
已完成
1 期
Study to Evaluate the Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of Prednisone in Healthy Male SubjectsHealthyNCT02268149Boehringer Ingelheim20
已完成
1 期
To Assess Safety, Tolerability and Pharmacokinetics of BI 443651 in Healthy Male VolunteersHealthyNCT02706925Boehringer Ingelheim63
撤回
1 期
A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy ParticipantsHepatic ImpairmentNCT02985632Bristol-Myers Squibb